JERUZALĖS VAISTINĖ, UAB

Company age: 31 y. 1 mo.

Update

Company overview

Company name JERUZALĖS VAISTINĖ, UAB
Company code 223284490
Registered address Vilnius, Jeruzalės g. 10, LT-08415
Registration date 1995-08-02 Company age: 31 y. 1 mo.
Phone Phone
Email None
Website None
Company manager For registered members only Log in
Revenue (2025) 59,578 € -52% History
Profit (2025) -8,372 € History
Share capital 2,896 €
Number of employees 0 History
Managed vehicles 0
Current SODRA debt No debt Read more
Days of debt to SODRA per year 0 days
Current VMI debt 0 € From: 2026-02-21 Read more
Financial statements All submitted
Legal form Private Limited Liability Company
NACE activity Retail sale of pharmaceutical products
Ownership form Private without foreign capital

Download a detailed company report

Make confident decisions with all the information about JERUZALĖS VAISTINĖ, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.

19.99 € + PVM Get report

Description

This description was generated by artificial intelligence.
JERUZALES VAISTINE, UAB (company code 223284490) is an operational private limited liability company registered in 1995. It is a privately owned Lithuanian company, governed by a CEO only, and classified as a micro-sized national private non-financial company. The company operates in Vilnius, at Jeruzales g. 10, Vilniaus m. sav., Vilniaus apskr. Its registered activity is EVRK G.47.73.00, retail sale of pharmaceutical products. The share capital amounts to EUR 2.9K.

Financial results show a weaker trend over the latest three financial years. Revenue declined from EUR 133.2K in 2023 to EUR 123.6K in 2024 and further to EUR 59.6K in 2025. The company reported a small profit of EUR 222 in 2023, then a loss of EUR 3.3K in 2024 and a larger loss of EUR 8.4K in 2025. Equity also decreased over the period, from EUR 22.5K in 2023 to EUR 14.9K in 2024 and EUR 6.5K in 2025. The company employed an average of 2 people in 2023 and 3 people in both 2024 and 2025.